Monoclonal antibody, Tyrosine kinase inhibitorPhase 3 trialInvestigational

Pembrolizumab + Vemurafenib

Generic name: pembrolizumab, vemurafenib

How it works

Blocks PD-1 and the BRAF V600E mutation, a genetic abnormality that drives cancer cell growth.

Cancer types

Melanoma— BRAF V600E mutation-positive

Efficacy

In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 16.6 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.